triazoles has been researched along with efinaconazole in 122 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (3.28) | 29.6817 |
| 2010's | 83 (68.03) | 24.3611 |
| 2020's | 35 (28.69) | 2.80 |
| Authors | Studies |
|---|---|
| Arika, T; Tatsumi, Y; Yamaguchi, H; Yokoo, M | 2 |
| Arika, T; Tatsum, Y; Yamaguchi, H; Yokoo, M | 1 |
| Kakehi, K; Senda, H; Tatsumi, Y; Yokoo, M | 1 |
| Elewski, BE; Ieda, C; Olin, JT; Pariser, DM; Pillai, R; Pollak, R; Ramakrishna, T; Rich, P; Senda, H; Smith, K; Watanabe, S | 1 |
| Fothergill, A; Jo Siu, WJ; Nakamura, T; Pillai, R; Senda, H; Sone, D; Tatsumi, Y | 1 |
| Bucko, AD; Kawabata, H; Oizumi, N; Olin, JT; Pillai, R; Tschen, EH | 1 |
| Inui, F; Iwata, A; Kangawa, Y; Nagashima, M; Nishiyama, Y; Pillai, R; Shibanushi, T; Siu, WJ; Tatsumi, Y | 1 |
| Rich, P | 2 |
| Jarratt, M; Kodera, N; Pillai, R; Siu, WJ; Smith, K; Yamakawa, E | 1 |
| Tosti, A | 1 |
| Dhillon, S; Patel, T | 1 |
| Lipner, S; Scher, RK | 1 |
| Kumagai, N; Shibasaki, M; Tamura, K | 1 |
| Fraser, K | 1 |
| Jim, SC; Kircik, LH; Routt, ET; Zeichner, JA | 1 |
| Arakawa, Y; Hosaka, S; Jo Siu, W; Katafuchi-Nagashima, M; Pillai, R; Sugimoto, N; Sugiura, K; Tatsumi, Y | 1 |
| Gupta, AK; Simpson, FC | 1 |
| Iwata, A; Katafuchi-Nagashima, M; Kumagai, N; Pillai, R; Sugiura, K; Tatsumi, Y; Watanabe, Y | 1 |
| Elewski, BE; Gupta, AK; Ieda, C; Kang, R; Kawabata, H; Olin, JT; Pillai, R; Sugarman, JL; Watanabe, S | 1 |
| Calvarese, B; Glynn, M; Jo, W; Minowa, K; Mutter, L; Nejishima, H; Pillai, R; Sanada, H; Senda, H | 1 |
| Pollak, RA | 1 |
| Glynn, M; Jo, W; Matsuuchi, H; Minowa, K; Mutter, L; Nejishima, H; Okamura, H; Pillai, R; Sanada, H | 1 |
| Joseph, WS; Vlahovic, TC | 1 |
| Kawabata, H; Kodera, N; Pillai, R; Sakamoto, M; Sugimoto, N; Tatsumi, Y; Yamakawa, E | 1 |
| Elewski, BE; Olin, JT; Pillai, R; Pollak, RA | 1 |
| Kircik, LH | 1 |
| Bhatia, N; Friedlander, SF; Gupta, AK; Kircik, L; Rosen, T; Stein Gold, L; Zirwas, MJ | 1 |
| Bhatt, V; Pillai, R | 1 |
| Lipner, SR; Scher, RK | 3 |
| Canavan, T; Cantrell, W; Elewski, B | 1 |
| Tatsumi, Y | 1 |
| Hanafusa, T; Hirohata, A; Ikegami, R; Mabuchi-Kiyohara, E | 1 |
| Arakawa, K; Hidaka, H; Honkura, Y; Ikeda, R; Katori, Y; Kawase, T; Nomura, K; Oshima, H | 1 |
| Bhatia, N | 1 |
| Gupta, AK; Pillai, R | 1 |
| Jellinek, NJ; Korotzer, A | 1 |
| Hussar, DA | 1 |
| Caldwell, B; Markinson, B | 1 |
| Rosen, T | 2 |
| Cohen, J; Joyce, C; Mikailov, A; Mostaghimi, A | 1 |
| Chanda, S; Coronado, D; Merchant, T; Vlahovic, TC; Zane, LT | 1 |
| Cernea, M; Gupta, AK | 1 |
| Dorval, E; Grace, Y; Machin, JD; Poulakos, M | 1 |
| Hossin, B; Murdan, S; Rizi, K | 1 |
| Koga, H; Maeda, J; Makimura, K; Nanjoh, Y; Toga, T; Tsuboi, R | 1 |
| Bhatia, N; Caldwell, B; Elewski, BE; Gupta, AK; Kircik, LH; Pariser, DM; Rosen, T; Tosti, A | 1 |
| Rosen, T; Stein Gold, LF | 3 |
| Chanda, S; Coronado, D; Del Rosso, J; Zane, LT | 1 |
| Lagrew, JP | 1 |
| Elewski, BE | 1 |
| Koski, R; Maki, K; Nybo, SE; Saunders, J | 1 |
| Hiruma, M; Ihn, H; Kano, R; Matsumoto, T; Noguchi, H | 2 |
| Gupta, AK; Korotzer, A | 1 |
| Gupta, AK; Studholme, C | 1 |
| Hirayanagi, K; Imai, A; Iwanaga, T; Kubota, N; Miyamae, A; Shibuya, K; Shimamura, T | 1 |
| Kawada, A; Oiso, N; Tatebayashi, M | 1 |
| Furuya, K; Hoshina, D; Yamaguchi, Y | 1 |
| Cook-Bolden, FE; Lin, T | 1 |
| Ahmadi, B; Alshahni, MM; Ansari, S; Badali, H; Makimura, K; Mirhendi, H; Rezaei-Matehkolaei, A; Shokoohi, GR; Vaezi, A | 1 |
| Adigun, CG; Gellings Lowe, N; Hall, SB; Joseph, WS; Rich, P; Vlahovic, TC; Zane, LT | 1 |
| Hasuko, M; Hirano, H; Inagaki, K; Motoba, K; Shiomi, R; Takahashi, Y; Tsuboi, R | 1 |
| Ilie, C; Pollak, RA | 1 |
| Cantrell, W; Elewski, BE; Lin, T | 1 |
| Imazu, Y; Suzuki, J; Uchida, E; Yamaura, K; Yoneta, Y | 1 |
| Hayashi, N; Imazu, Y; Suzuki, J; Uchida, E; Yamaura, K; Yoneta, Y | 1 |
| Baltazar, LM; Costa-Orlandi, CB; Friedman, AJ; Friedman, JM; Mendes-Giannini, MJS; Mordorski, B; Nosanchuk, JD | 1 |
| Asao, K; Fukushima, S; Hirose, M; Hiruma, M; Ihn, H; Matsumoto, T; Noguchi, H | 1 |
| Bonhert, K; Dorizas, A; Sadick, NS | 1 |
| Fukushima, S; Hirose, M; Hiruma, M; Ihn, H; Matsumoto, T; Noguchi, H; Yaguchi, T | 1 |
| Karasawa, T; Kumagai, N; Oriez, R; Shibasaki, M | 1 |
| Hur, MS; Jung, WH; Lee, YW; Park, M | 1 |
| Ko, D; Lipner, SR | 1 |
| Abe, M; Fujii, M; Fukuzawa, M; Hata, Y; Hattori, N; Iozumi, K; Ito, Y; Kasai, H; Katayama, I; Kato, F; Kato, I; Kiryu, H; Kodama, K; Kusuhara, M; Maruyama, R; Mayama, J; Mochizuki, T; Muramoto, F; Nakasu, I; Nishimoto, S; Nomiyama, T; Oh-I, T; Omi, T; Onoduka, T; Sato, T; Sei, Y; Seishima, M; Shimoyama, H; Shindo, M; Sugiura, K; Takahashi, H; Takeda, O; Takenaka, M; Tomizawa, K; Tsuboi, R; Uesugi, T; Watanabe, S; Yamamoto, O; Yamanaka, K; Yasuda, H | 1 |
| Burgalassi, S; Celandroni, F; Ghelardi, E; Mazzantini, D; Monti, D; Tampucci, S; Vecchione, A | 1 |
| Kawai, M | 1 |
| Lin, K; Lipner, SR | 1 |
| Koo, KT; Lee, BC; Na, J; Pangeni, R; Park, JW | 1 |
| Harada, K; Inagaki, K; Kampirapap, K; Koga, H; Maeda, J; Makimura, K; Nanjoh, Y; Neki, D; Reangchainam, S; Tsuboi, R; Yuasa, K | 1 |
| Kuwano, Y; Sei, Y; Shimoyama, H | 1 |
| Ahmad Nasrollahi, S; Azizzadeh-Roodpishi, S; Dowlatiy, Y; Ehsani, AH; Fattahi, A; Firooz, A; Ghasemi, Z; Malakooti, S; Naeimifar, A; Samadi, A | 1 |
| Lipner, SR; Wang, Y | 1 |
| Abastabar, M; Ahangarkani, F; Badali, H; Fakhim, H; Haghani, I; Ilkit, M; Javidnia, J; Meis, JF; Taheri Rizi, Z | 1 |
| Hamedani, E; Harkless, L; Navarrete, R; Seun, J; Shofler, D; Thamby, R | 1 |
| Geizhals, S; Lipner, SR; Wu, AG | 1 |
| Gupta, AK; Piguet, V; Shear, NH; Venkataraman, M | 1 |
| Eichenfield, LF; Elewski, B; Guenin, E; Gupta, AK; Pillai, R; Rosen, T; Sugarman, JL; Vlahovic, TC | 1 |
| Abe, N; Anzawa, K; Fukumoto, T; Komatsu-Fujii, T; Nonoyama, S; Ogawa, M; Ookura, T; Tanabe, H | 1 |
| Fujimoto, K; Mayumi, N; Otsuka, Y; Saeki, H; Yamaguchi, H | 1 |
| Eichenfield, LF; Elewski, B; Guenin, E; Gupta, AK; Pillai, R; Rosen, T; Stein Gold, L; Sugarman, JL; Vlahovic, TC | 1 |
| Geizhals, S; Lipner, SR | 1 |
| Cooper, EA; Gupta, AK | 1 |
| Hirakawa, S; Inagaki, K; Nagai, H; Nakamura, A | 1 |
| Agrawal, V; Mishra, S; Patel, M; Patel, R; Thanki, K | 1 |
| Choi, YS; Ho, MJ; Jang, SW; Kang, MJ; Kim, EA; Kim, JS; Park, DW; Park, JS | 1 |
| Ansari, S; Goodarzi, S; Javidnia, J; Maryami, F; Mirhendi, H; Rasekh-Jahromi, A; Rezaei-Matehkolaei, A; Romeo, O; Shokoohi, G | 1 |
| Aoi, J; Fukushima, S; Kashiwada-Nakamura, K; Kubo, M; Makino, K; Noguchi, H | 1 |
| Gupta, AK; Vlahovic, TC | 1 |
| Asharani, IV; Govindarajan, S | 1 |
| Abe, M; Fujii, M; Fukuzawa, M; Hattori, N; Iozumi, K; Ito, Y; Kasai, H; Kato, F; Kato, I; Kiryu, H; Kodama, K; Kusuhara, M; Maruyama, R; Mayama, J; Mochizuki, T; Muramoto, F; Nakasu, I; Nishimoto, S; Oh-I, T; Omi, T; Onoduka, T; Seishima, M; Shimoyama, H; Shindo, M; Sugiura, K; Takahashi, H; Takeda, O; Takenaka, M; Tateishi, Y; Tomizawa, K; Tsuboi, R; Uesugi, T; Watanabe, S; Watanabe-Okada, E; Yamamoto, O; Yamanaka, K; Yasuda, H | 1 |
| Anbalagan, N; Guenin, EP; Gupta, AK; Venkataraman, M | 1 |
| Abramovits, W; Guenin, EP; Gupta, AK; Venkataraman, M | 1 |
| Bila, NM; Costa-Orlandi, CB; Friedman, AJ; Friedman, JM; Martinez, LR; Mendes-Giannini, MJS; Nosanchuk, JD | 1 |
| Murota, H; Nishimoto, K; Takenaka, M | 1 |
| Garoufalis, MG | 1 |
| Guillot, J; Rezaei-Matehkolaei, A; Shamsizadeh, F; Shariat Nabavi, M; Taghipour, S; Zarei Mahmoudabadi, A | 1 |
| Gupta, AK; Talukder, M | 1 |
| Masumoto, A; Matsuda, Y; Nakamura, S; Sugiura, K; Takagi, M; Tatsumi, Y | 1 |
| Hiruma, M; Kano, R; Kimura, U; Kubo, M; Matsumoto, T; Noguchi, H; Tanaka, M; Yaguchi, T; Yamada, T | 1 |
| Iijima, S; Murayama, K; Takayama, N | 1 |
| Abastabar, M; Aghili, SR; Badali, H; Faeli, L; Haghani, I; Hedayati, MT; Javan-Nikkhah, M; Javidnia, J; Kachuei, R; Katiraee, F; Khodavaisy, S; M S Al Hatmi, A; Mohammadi, R; Najafzadeh, MJ; Nazeri, M; Nosratabadi, M; Salimi, M; Shokohi, T; Zarrinfar, H | 1 |
| Fukushima, S; Higuchi, S; Hiruma, M; Kano, R; Kashiwada-Nakamura, K; Kubo, M; Matsumoto, T; Noguchi, H; Satoh, T; Yaguchi, T | 1 |
| Chen, FE; Ju, Z; Kaliaperumal, K; Li, M; Li, Z; Xu, S | 1 |
19 review(s) available for triazoles and efinaconazole
| Article | Year |
|---|---|
What is new in fungal pharmacotherapeutics?
Topics: Allylamine; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Education, Medical, Continuing; Humans; Imidazoles; Itraconazole; Onychomycosis; Tinea Pedis; Triazoles | 2014 |
The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials.
Topics: Administration, Topical; Aged; Antifungal Agents; Clinical Trials, Phase III as Topic; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Pharmaceutical Solutions; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Triazoles | 2014 |
Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Triazoles | 2014 |
Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach.
Topics: Administration, Topical; Antifungal Agents; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Nails; Onychomycosis; Permeability; Triazoles | 2014 |
Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape.
Topics: Anti-Infective Agents, Local; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Onychomycosis; Pharmaceutical Solutions; Treatment Outcome; Triazoles | 2015 |
[Pharmacological characteristics and clinical results of efinaconazole (Clenafin® Topical Solution 10%), a novel anti-onychomycosis drug].
Topics: Animals; Antifungal Agents; Clinical Trials as Topic; Drug Resistance; Humans; Onychomycosis; Pharmaceutical Solutions; Triazoles | 2015 |
Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail.
Topics: Administration, Topical; Animals; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Triazoles | 2015 |
New drugs 2015, part 3.
Topics: Acids, Carbocyclic; Benzoxazines; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cephalosporins; Cyclopentanes; Drug Approval; Drug Combinations; Drug Therapy; Glucagon-Like Peptides; Guanidines; Humans; Imidazoles; Immunoglobulin Fc Fragments; Interferon-beta; Isoquinolines; Penicillanic Acid; Polyethylene Glycols; Pyridines; Quinuclidines; Recombinant Fusion Proteins; Tazobactam; Triazoles; United States; United States Food and Drug Administration | 2015 |
Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prospective Studies; Randomized Controlled Trials as Topic; Sex Factors; Treatment Outcome; Triazoles; Young Adult | 2015 |
Efinaconazole and Tavaborole.
Topics: Administration, Topical; Animals; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Foot Dermatoses; Humans; Microbial Sensitivity Tests; Onychomycosis; Triazoles | 2017 |
Antifungal agents for onychomycosis: new treatment strategies to improve safety.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Chemical and Drug Induced Liver Injury; Ciclopirox; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2016 |
Tavaborole, Efinaconazole, and Luliconazole: Three New Antimycotic Agents for the Treatment of Dermatophytic Fungi.
Topics: Administration, Topical; Animals; Antifungal Agents; Arthrodermataceae; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatomycoses; Humans; Imidazoles; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2017 |
Ungual hyalohyphomycosis caused by Fusarium proliferatum in an immunocompetent patient.
Topics: Administration, Topical; Aged; Antifungal Agents; Female; Foot Dermatoses; Fusariosis; Fusarium; Humans; Hyphae; Naphthalenes; Onychomycosis; Terbinafine; Triazoles | 2017 |
Onychomycosis: Treatment and prevention of recurrence.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Fluconazole; Humans; Itraconazole; Laser Therapy; Nanoparticles; Onychomycosis; Photochemotherapy; Plasma Gases; Prognosis; Pulse Therapy, Drug; Risk Factors; Secondary Prevention; Severity of Illness Index; Terbinafine; Triazoles | 2019 |
Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Drug Resistance, Fungal; Humans; Imidazoles; Keratins; Nails; Onychomycosis; Solutions; Triazoles; Trichophyton | 2019 |
A Timeline of Onychomycosis Therapy and Future Directions.
Topics: Administration, Topical; Antifungal Agents; Humans; Itraconazole; Nail Diseases; Onychomycosis; Terbinafine; Triazoles | 2020 |
Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.
Topics: Administration, Topical; Adult; Antifungal Agents; Child; Humans; Onychomycosis; Pediatrics; Triazoles | 2022 |
One size does not fit all: the need for individualized treatment based on factors that may affect the therapeutic outcome of efinaconazole 10% solution for the treatment of toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Nails; Onychomycosis; Quality of Life; Treatment Outcome; Triazoles | 2021 |
Efinaconazole in Onychomycosis.
Topics: Administration, Topical; Adult; Antifungal Agents; Child; Female; Humans; Onychomycosis; Triazoles | 2022 |
24 trial(s) available for triazoles and efinaconazole
| Article | Year |
|---|---|
Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Triazoles; Young Adult | 2013 |
Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study.
Topics: Administration, Topical; Adult; Antifungal Agents; Chemistry, Pharmaceutical; Double-Blind Method; Female; Humans; Male; Middle Aged; Nails; Onychomycosis; Pharmaceutical Solutions; Research Design; Treatment Outcome; Triazoles; Young Adult | 2013 |
Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Ethnicity; Female; Half-Life; Humans; Male; Middle Aged; Nails; Onychomycosis; Pharmaceutical Solutions; Triazoles; Young Adult | 2013 |
Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Diabetes Mellitus; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2014 |
Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Drug Delivery Systems; Female; Follow-Up Studies; Foot Dermatoses; Humans; In Vitro Techniques; Male; Microbial Sensitivity Tests; Middle Aged; Nails; Onychomycosis; Permeability; Triazoles; Trichophyton | 2014 |
Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
Topics: Administration, Topical; Antifungal Agents; Female; Foot Dermatoses; Humans; Male; Middle Aged; Nails; Onychomycosis; Permeability; Treatment Outcome; Triazoles | 2014 |
Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early.
Topics: Administration, Topical; Adult; Antifungal Agents; Disease Progression; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prospective Studies; Time Factors; Treatment Outcome; Triazoles | 2015 |
Managing Assessments and Expectations: Patient Responses Following Therapy With Efinaconazole Topical Solution, 10%.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Nails; Onychomycosis; Patient Satisfaction; Severity of Illness Index; Treatment Outcome; Triazoles; Young Adult | 2015 |
The Presence of an Air Gap Between the Nail Plate and Nail Bed in Onychomycosis Patients: Treatment Implications for Topical Therapy.
Topics: Administration, Cutaneous; Adult; Aged; Air; Antifungal Agents; Female; Fluorescein; Foot Dermatoses; Humans; Male; Middle Aged; Nails; Onychomycosis; Pharmaceutical Vehicles; Severity of Illness Index; Triazoles | 2015 |
Prognostic Factors for Complete Cure Following Treatment of Mild and Moderate Toenail Onychomycosis With Efinaconazole Topical Solution 10.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prognosis; Severity of Illness Index; Treatment Outcome; Triazoles; Young Adult | 2015 |
Efinaconazole Topical Solution, 10% Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Onychomycosis; Tinea Pedis; Treatment Outcome; Triazoles; Young Adult | 2015 |
Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis.
Topics: Administration, Oral; Administration, Topical; Algorithms; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Health Care Costs; Humans; Hydroxides; Naphthalenes; Onychomycosis; Periodic Acid-Schiff Reaction; Potassium Compounds; Potentially Inappropriate Medication List; Terbinafine; Triazoles | 2016 |
A financial perspective on the topical treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Female; Follow-Up Studies; Foot Dermatoses; Humans; Male; Onychomycosis; Risk Assessment; Treatment Outcome; Triazoles | 2016 |
Topical Treatment of Onychomycosis and Clinically Meaningful Outcomes.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Follow-Up Studies; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles; Young Adult | 2016 |
Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles; Young Adult | 2017 |
Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prognosis; Severity of Illness Index; Treatment Outcome; Triazoles; Young Adult | 2018 |
Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd:YAG laser for treatment of toenail onychomycosis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Combined Modality Therapy; Female; Follow-Up Studies; Foot Dermatoses; Humans; Laser Therapy; Lasers, Solid-State; Male; Middle Aged; Onychomycosis; Patient Satisfaction; Photography; Statistics, Nonparametric; Treatment Outcome; Triazoles | 2019 |
Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study.
Topics: Administration, Topical; Aged; Antifungal Agents; Drug-Related Side Effects and Adverse Reactions; Female; Foot Dermatoses; Humans; Incidence; Long-Term Care; Male; Middle Aged; Onychomycosis; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2019 |
Efinaconazole topical solution 10%: Formulation and efficacy assessment in the treatment of toenail onychomycosis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Female; Foot; Humans; Male; Middle Aged; Nail Diseases; Nails; Onychomycosis; Pilot Projects; Triazoles; Young Adult | 2020 |
Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Blood Glucose; Diabetes Complications; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2020 |
Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis.
Topics: Administration, Topical; Adolescent; Antifungal Agents; Child; Foot Dermatoses; Humans; Multicenter Studies as Topic; Onychomycosis; Triazoles | 2020 |
Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.
Topics: Administration, Cutaneous; Adolescent; Antifungal Agents; Child; Female; Foot Dermatoses; Humans; Male; Onychomycosis; Solutions; Treatment Outcome; Triazoles | 2021 |
Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
Topics: Administration, Topical; Adolescent; Antifungal Agents; Area Under Curve; Child; Female; Follow-Up Studies; Foot Dermatoses; Fungi; Humans; Male; Onychomycosis; Severity of Illness Index; Solutions; Treatment Outcome; Triazoles | 2020 |
Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis.
Topics: Administration, Cutaneous; Aged; Antifungal Agents; Drug Administration Schedule; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2021 |
79 other study(ies) available for triazoles and efinaconazole
| Article | Year |
|---|---|
In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs.
Topics: Animals; Antifungal Agents; Blood Proteins; Candida; Candidiasis, Cutaneous; Culture Media; Disease Models, Animal; Guinea Pigs; Hair; Microbial Sensitivity Tests; Tinea Pedis; Treatment Outcome; Triazoles; Trichophyton | 2001 |
KP-103, a novel triazole derivative, is effective in preventing relapse and successfully treating experimental interdigital tinea pedis and tinea corporis in guinea pigs.
Topics: Animals; Antibiotic Prophylaxis; Antifungal Agents; Aspergillus flavus; Disease Models, Animal; Drug Evaluation, Preclinical; Guinea Pigs; Keratins; Male; Microbial Sensitivity Tests; Secondary Prevention; Tinea; Tinea Pedis; Toes; Treatment Outcome; Triazoles; Trichophyton | 2002 |
In vivo fungicidal effect of KP-103 in a guinea pig model of interdigital tinea pedis determined by using a new method for removing the antimycotic carryover effect.
Topics: Animals; Antifungal Agents; Colony Count, Microbial; Culture Media; Drug Evaluation, Preclinical; Guinea Pigs; Heterocyclic Compounds; Imidazoles; Male; Microbial Sensitivity Tests; Models, Animal; Time Factors; Tinea Pedis; Treatment Outcome; Triazoles; Trichophyton | 2002 |
Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.
Topics: Administration, Oral; Administration, Topical; Animals; Antifungal Agents; Guinea Pigs; Male; Microbial Sensitivity Tests; Morpholines; Naphthalenes; Onychomycosis; Terbinafine; Tinea Pedis; Triazoles; Trichophyton | 2002 |
Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Topics: Antifungal Agents; Aspergillus; Candida; Cryptococcus; Itraconazole; Microbial Sensitivity Tests; Morpholines; Naphthalenes; Onychomycosis; Pseudallescheria; Scopulariopsis; Terbinafine; Triazoles; Trichophyton; Trichosporon | 2013 |
Mechanism of action of efinaconazole, a novel triazole antifungal agent.
Topics: 14-alpha Demethylase Inhibitors; Antifungal Agents; Candida albicans; Dose-Response Relationship, Drug; Ergosterol; Hyphae; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Sterols; Triazoles; Trichophyton | 2013 |
Topical treatment of onychomycosis with efinaconazole solution 10%.
Topics: Adult; Antifungal Agents; Foot Dermatoses; Humans; Male; Onychomycosis; Triazoles; Trichophyton | 2013 |
Efinaconazole solution 10%: topical antifungal therapy for toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Recurrence; Triazoles | 2013 |
Efinaconazole: first global approval.
Topics: Administration, Topical; Animals; Antifungal Agents; Drug Approval; Humans; Onychomycosis; Pharmaceutical Solutions; Triazoles | 2013 |
Onychomycosis: current and future therapies.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Debridement; Foot Dermatoses; Hand Dermatoses; Humans; Laser Therapy; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2014 |
An enantioselective synthesis of the key intermediate for triazole antifungal agents; application to the catalytic asymmetric synthesis of efinaconazole (Jublia).
Topics: Antifungal Agents; Catalysis; Molecular Structure; Stereoisomerism; Triazoles | 2014 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Topics: Administration, Topical; Animals; Antifungal Agents; Guinea Pigs; Humans; In Vitro Techniques; Keratins; Microbial Sensitivity Tests; Nails; Onychomycosis; Tinea; Triazoles; Trichophyton | 2014 |
Efinaconazole (Jublia) for the treatment of onychomycosis.
Topics: 14-alpha Demethylase Inhibitors; Administration, Topical; Clinical Trials as Topic; Ergosterol; Humans; Microbial Sensitivity Tests; Onychomycosis; Triazoles | 2014 |
In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal.
Topics: Administration, Topical; Animals; Antifungal Agents; Colony Count, Microbial; Drug Resistance, Fungal; Guinea Pigs; Microbial Sensitivity Tests; Onychomycosis; Triazoles; Trichophyton | 2014 |
News drugs and dosage forms.
Topics: Anti-HIV Agents; Antifungal Agents; Atazanavir Sulfate; Drug Combinations; Humans; Ketorolac; Oligopeptides; Phenylephrine; Pyridines; Testosterone; Triazoles | 2014 |
Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment.
Topics: Administration, Cutaneous; Administration, Topical; Animals; Antifungal Agents; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Male; Mice; Mice, Inbred ICR; No-Observed-Adverse-Effect Level; Onychomycosis; Pharmaceutical Solutions; Rats; Rats, Sprague-Dawley; Skin; Swine; Swine, Miniature; Time Factors; Triazoles | 2014 |
Efinaconazole topical solution (Jublia) for onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Drug Approval; Humans; Onychomycosis; Triazoles; United States; United States Food and Drug Administration | 2014 |
Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole.
Topics: Animals; Animals, Newborn; Antifungal Agents; Dose-Response Relationship, Drug; Embryonic Development; Estrous Cycle; Female; Fertility; Fetal Death; Male; Rabbits; Rats; Reproduction; Triazoles | 2015 |
Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Chemistry, Pharmaceutical; Drug Delivery Systems; Foot Dermatoses; Humans; Nail Diseases; Nails; Onychomycosis; Permeability; Pharmaceutical Solutions; Solubility; Triazoles | 2015 |
Management of onychomycosis and co-existing tinea pedis.
Topics: Administration, Topical; Antifungal Agents; Clinical Trials as Topic; Humans; Onychomycosis; Severity of Illness Index; Tinea Pedis; Triazoles | 2015 |
Report of a case of a dermatophytoma successfully treated with topical efinaconazole 10% solution.
Topics: Administration, Topical; Aged; Antifungal Agents; Foot Dermatoses; Humans; Male; Naphthalenes; Onychomycosis; Terbinafine; Tinea; Treatment Outcome; Triazoles | 2015 |
Contact dermatitis caused by efinaconazole solution for treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Dermatitis, Allergic Contact; Humans; Male; Middle Aged; Onychomycosis; Patch Tests; Solutions; Triazoles | 2015 |
Effect of intratympanic application of efinaconazole 10 % solution in the guinea pig.
Topics: Animals; Antifungal Agents; Ear, Middle; Evoked Potentials, Auditory, Brain Stem; Gentamicins; Guinea Pigs; Hair Cells, Auditory; Hearing Loss; Injection, Intratympanic; Male; Solutions; Triazoles | 2016 |
Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Nails; Onychomycosis; Triazoles | 2016 |
How effective is efinaconazole in the management of onychomycosis?
Topics: Antifungal Agents; Disease Management; Humans; Nails; Onychomycosis; Pharmaceutical Solutions; Triazoles | 2016 |
Application of Hansen Solubility Parameters to predict drug-nail interactions, which can assist the design of nail medicines.
Topics: Adolescent; Adult; Antifungal Agents; Ciclopirox; Drug Interactions; Female; Humans; Keratins; Male; Middle Aged; Morpholines; Nail Diseases; Nails; Naphthalenes; Onychomycosis; Pharmaceutical Preparations; Pyridones; Solubility; Terbinafine; Triazoles; Young Adult | 2016 |
[In vitro Antifungal Activity of Luliconazole against Trichophyton spp].
Topics: Allylamine; Antifungal Agents; Drug Resistance, Fungal; Imidazoles; Microbial Sensitivity Tests; Naphthalenes; Pyridines; Terbinafine; Thiocarbamates; Triazoles; Trichophyton | 2016 |
Onychomycosis: Strategies to Minimize Recurrence.
Topics: Administration, Topical; Antifungal Agents; Comorbidity; Diabetes Mellitus; Drug Administration Schedule; Humans; Itraconazole; Morpholines; Naphthalenes; Onychomycosis; Prevalence; Recurrence; Terbinafine; Tinea Pedis; Triazoles | 2016 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles; United States | 2016 |
Introduction.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Foot Dermatoses; Humans; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles | 2016 |
Using Topical Antifungal Medications: Instructions for patients.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Drug Administration Schedule; Foot Dermatoses; Humans; Onychomycosis; Pyridones; Triazoles | 2016 |
Response to "A financial perspective on the topical treatment of onychomycosis".
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Drug Costs; Female; Foot Dermatoses; Humans; Male; Onychomycosis; Sensitivity and Specificity; Severity of Illness Index; Triazoles | 2016 |
Ungual aspergillosis successfully treated with topical efinaconazole.
Topics: Administration, Topical; Aged; Antifungal Agents; Aspergillosis; Female; Humans; Onychomycosis; Triazoles | 2017 |
Tinea and Onychomycosis.
Topics: Administration, Cutaneous; Antifungal Agents; Humans; Imidazoles; Onychomycosis; Recurrence; Tinea; Tinea Pedis; Triazoles | 2016 |
Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Clinical Trials, Phase III as Topic; Humans; Onychomycosis; Solutions; Triazoles | 2016 |
Comparison of Characteristics of Two Topical Therapeutic Agents for Onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Fungal; Humans; Imidazoles; In Vitro Techniques; Nails; Onychomycosis; Solutions; Triazoles; Trichophyton | 2016 |
Allergic contact dermatitis caused by efinaconazole: positive patch test reactions up to 0.1% pet.
Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Allergic Contact; Foot Dermatoses; Humans; Male; Onychomycosis; Patch Tests; Triazoles | 2017 |
Onychomadesis caused by efinaconazole.
Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Allergic Contact; Foot Dermatoses; Humans; Male; Nail Diseases; Onychomycosis; Patch Tests; Triazoles | 2017 |
Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients.
Topics: Administration, Topical; Antifungal Agents; Female; Foot Dermatoses; Hispanic or Latino; Humans; Male; Middle Aged; Onychomycosis; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles; United States | 2017 |
Topics: Adult; Antifungal Agents; Ascomycota; Child, Preschool; Drug Resistance, Fungal; Female; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Mycoses; Triazoles; Yeasts; Young Adult | 2017 |
Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Onychomycosis; Pyridones; Research Design; Treatment Outcome; Triazoles; United States | 2017 |
[Affinity of Luliconazole for Human Nail Derived Keratin].
Topics: Humans; Imidazoles; Keratins; Nails; Onychomycosis; Triazoles | 2017 |
[Current Status of Onychomycosis Topical Therapy Conducted at Home].
Topics: Antifungal Agents; Caregivers; Home Care Services; Humans; Infectious Disease Transmission, Professional-to-Patient; Onychomycosis; Triazoles | 2018 |
[Role of Pharmacists in Topical Therapy for Onychomycosis in the Home-care Setting].
Topics: Administration, Topical; Antifungal Agents; Community Pharmacy Services; Home Care Services; Humans; Japan; Onychomycosis; Patient Compliance; Pharmacists; Prevalence; Professional Role; Quality of Life; Triazoles | 2018 |
Nitric Oxide Releasing Nanoparticles as a Strategy to Improve Current Onychomycosis Treatments.
Topics: Administration, Topical; Animals; Antifungal Agents; Disease Models, Animal; Drug Carriers; Drug Liberation; Drug Synergism; Drug Therapy, Combination; Humans; Mice; Microbial Sensitivity Tests; Nanoparticles; Naphthalenes; Nitric Oxide; Onychomycosis; Permeability; Prescription Fees; Terbinafine; Treatment Outcome; Triazoles; Trichophyton | 2018 |
Topical efinaconazole: A promising therapeutic medication for tinea unguium.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifungal Agents; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Photography; Treatment Outcome; Triazoles | 2018 |
Onychomycosis caused by Aspergillus subramanianii.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antifungal Agents; Aspergillosis; Aspergillus; Female; Foot Dermatoses; Humans; Hyphae; Japan; Microscopy; Onychomycosis; Terbinafine; Triazoles; Young Adult | 2018 |
anti-Selective Catalytic Asymmetric Nitroaldol Reaction of α-Keto Esters: Intriguing Solvent Effect, Flow Reaction, and Synthesis of Active Pharmaceutical Ingredients.
Topics: Alcohols; Catalysis; Esters; Furans; Ketones; Neodymium; Nitro Compounds; Quinazolines; Sodium; Solvents; Stereoisomerism; Triazoles | 2018 |
Evaluation of drug susceptibility test for Efinaconazole compared with conventional antifungal agents.
Topics: Antifungal Agents; Candida albicans; Humans; Microbial Sensitivity Tests; Onychomycosis; Tinea; Triazoles; Trichophyton | 2019 |
Optimizing topical therapy for onychomycosis: the importance of patient education.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Humans; Medication Adherence; Onychomycosis; Patient Education as Topic; Triazoles | 2018 |
Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
Topics: Animals; Antifungal Agents; Biological Transport; Cattle; Ciclopirox; Drug Resistance, Fungal; Hoof and Claw; Humans; Keratins; Microbial Sensitivity Tests; Microtomy; Models, Biological; Mutation; Nails; Permeability; Protein Binding; Tinea; Triazoles; Trichophyton | 2019 |
Modeling of usage and estimation of cost for efinaconazole 10% topical solution in the treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Drug Costs; Foot Dermatoses; Healthy Volunteers; Humans; Nails; Onychomycosis; Solutions; Triazoles; United States | 2020 |
Preparation and
Topics: Administration, Topical; Animals; Antifungal Agents; Disease Models, Animal; Guinea Pigs; Humans; In Vitro Techniques; Male; Membranes, Artificial; Nails; Onychomycosis; Permeability; Skin; Skin Absorption; Tinea; Triazoles; Trichophyton | 2019 |
In vitro antifungal activity of luliconazole against nondermatophytic moulds.
Topics: Amphotericin B; Antifungal Agents; Clotrimazole; Fluconazole; Fungi; Humans; Imidazoles; Itraconazole; Ketoconazole; Miconazole; Microbial Sensitivity Tests; Morpholines; Sequence Analysis, DNA; Terbinafine; Triazoles; Voriconazole | 2020 |
Retrospective Survey of Treatment Outcomes of Efinaconazole 10% Solution and Luliconazole 5% Solution for Onychomycosis in Our Facility.
Topics: Administration, Topical; Adult; Aged; Female; Humans; Imidazoles; Male; Middle Aged; Onychomycosis; Retrospective Studies; Solutions; Treatment Outcome; Triazoles | 2019 |
Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration.
Topics: Administration, Topical; Adverse Drug Reaction Reporting Systems; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Erythema; Humans; Nails; Onychomycosis; Pigmentation; Retrospective Studies; Solutions; Treatment Failure; Triazoles; United States; United States Food and Drug Administration | 2020 |
Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates.
Topics: Antifungal Agents; Aspergillosis; Aspergillus; Microbial Sensitivity Tests; Triazoles | 2020 |
Retrospective study of factors affecting medication adherence in patients prescribed efinaconazole 10% solution for onychomycosis.
Topics: Administration, Topical; Age Factors; Antifungal Agents; Drug Prescriptions; Humans; Medication Adherence; Onychomycosis; Prescription Fees; Retrospective Studies; Triazoles | 2021 |
Usefulness of topical efinaconazole for infantile tinea capitis due to Microsporum canis diagnosed with Wood's light.
Topics: Humans; Microsporum; Tinea Capitis; Triazoles | 2020 |
Contact Dermatitis Caused by Efinaconazole and Luliconazole.
Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Contact; Epitopes; Foot Dermatoses; Humans; Imidazoles; Male; Patch Tests; Triazoles | 2021 |
A comparative study between two antifungal agents, Luliconazole and Efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model.
Topics: Administration, Topical; Animals; Antifungal Agents; Disease Models, Animal; Guinea Pigs; Imidazoles; Male; Specific Pathogen-Free Organisms; Tinea; Triazoles; Trichophyton | 2021 |
Design and evaluation of microemulsion-based efinaconazole formulations for targeted treatment of onychomycosis through transungual route: Ex vivo and nail clipping studies.
Topics: Antifungal Agents; Arthrodermataceae; Emulsions; Humans; Nails; Onychomycosis; Triazoles | 2021 |
Effect of Penetration Enhancers on Toenail Delivery of Efinaconazole from Hydroalcoholic Preparations.
Topics: Administration, Topical; Animals; Antifungal Agents; Cattle; Diffusion; Drug Carriers; Drug Delivery Systems; Hoof and Claw; Onychomycosis; Permeability; Propylene Glycol; Triazoles | 2021 |
Molecular identification and antifungal susceptibility profiles of Candida dubliniensis and Candida africana isolated from vulvovaginal candidiasis: A single-centre experience in Iran.
Topics: Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; DNA, Fungal; Female; Fungal Proteins; Humans; Imidazoles; Iran; Membrane Glycoproteins; Microbial Sensitivity Tests; Middle Aged; Prevalence; Triazoles | 2021 |
Topical efinaconazole: A sequential combination therapy with oral terbinafine for refractory tinea unguium.
Topics: Administration, Topical; Antifungal Agents; Humans; Onychomycosis; Terbinafine; Triazoles | 2021 |
Development and Validation of a LC-MS/MS Method for the Profiling of Impurities Formed during Stress Study of Antifungal Agent-Efinaconazole.
Topics: Antifungal Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Stability; Hydrolysis; Oxidation-Reduction; Photolysis; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles | 2022 |
Clinical effectiveness of efinaconazole 10% solution for treatment of onychomycosis with longitudinal spikes.
Topics: Administration, Topical; Antifungal Agents; Humans; Onychomycosis; Treatment Outcome; Triazoles | 2021 |
JUBLIA (Efinaconazole 10% Solution) in the Treatment of Pediatric Onychomycosis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Child; Foot Dermatoses; Humans; Onychomycosis; Terbinafine; Triazoles | 2021 |
Nitric Oxide-Releasing Nanoparticles Are Similar to Efinaconazole in Their Capacity to Eradicate
Topics: Antifungal Agents; Arthrodermataceae; Biofilms; Microbial Sensitivity Tests; Nanoparticles; Nitric Oxide; Triazoles; Trichophyton | 2021 |
Chronological evaluation of treatment effect for tinea unguium with efinaconazole: Possibility of an early estimation of treatment effects.
Topics: Administration, Topical; Antifungal Agents; Humans; Onychomycosis; Triazoles | 2021 |
Total Dystrophic Onychomycosis Successfully Treated with Efinaconazole Topical Solution in Times of Coronavirus Disease of 2019: A Case Study.
Topics: Administration, Topical; Adult; Antifungal Agents; Coronavirus; Female; Foot Dermatoses; Humans; Onychomycosis; Treatment Outcome; Triazoles | 2022 |
In vitro activities of 8 antifungal agents against geophilic dermatophyte isolates.
Topics: Antifungal Agents; Arthrodermataceae; Imidazoles; Itraconazole; Microbial Sensitivity Tests; Terbinafine; Triazoles | 2022 |
A novel method for predicting the efficacy of topical drugs on onychomycosis: A comparison of efinaconazole and luliconazole.
Topics: Administration, Topical; Antifungal Agents; Humans; Imidazoles; Nails; Onychomycosis; Triazoles | 2022 |
Effective Response of Dermatophytoma Caused by Terbinafine-Resistant Trichophyton interdigitale Solely to Topical Efinaconazole.
Topics: Antifungal Agents; Arthrodermataceae; Drug Resistance, Fungal; Microbial Sensitivity Tests; Terbinafine; Triazoles; Trichophyton | 2022 |
[ANALYSIS OF PATCH TEST RESULTS FOR INDIVIDUAL INGREDIENTS IN PATIENTS WITH ALLERGIC CONTACT DERMATITIS CAUSED BY 10% EFINACONAZOLE NAIL SOLUTION].
Topics: Allergens; Dermatitis, Allergic Contact; Ethanol; Humans; Patch Tests; Petrolatum; Triazoles | 2022 |
In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasising on the potent inhibitory effect of efinaconazole compared to other drugs.
Topics: Antifungal Agents; Fusariosis; Fusarium; Humans; Iran; Microbial Sensitivity Tests; Triazoles | 2023 |
Onychomycosis Caused by Talaromyces muroii Successfully Treated with Efinaconazole.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Talaromyces; Triazoles | 2023 |
A Chemo-Enzymatic Approach for Preparing Efinaconazole with High Optical Yield.
Topics: Benzoin; Ketones; Thiamine Pyrophosphate; Triazoles | 2023 |